Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

New This Week On Slingshot Insights SA Premium Service: 1/28/2019

|Includes: Astellas Pharma Inc. (ALPMY), ECYT, JNJ, NVAX, PFE, PGNX
Summary

This week we have Expert Calls on: ALPMY, JNJ, ECYT, PGNX, PFE, NVAX.

This series of instablog posts will highlight the most recently executed transcripts being added to the “Become the Smart Money” , Slingshot Insights Seeking Alpha Premium service. In these blog posts we will give you a bit more information about the subject matter experts we interviewed, the topics covered, and relevant companies. We hope that these brief overviews, combined with our free content and articles, will display what we believe is the content’s unique value to our members. Please don’t hesitate to directly ask us questions at any time via SeekingAlpha Direct message or email to info@slingshotinsights.com.

Why Do Expert Research?

While many individuals we speak to are unaware of the role expert interviews play for many professional investors, it is a $600mm industry. Many funds pay in excess of $100,000 a year just for a relationship with an expert network and over a thousand dollars per call. While these numbers sound staggering, many investors consider them well worth the money. Slingshot Insights’ sharing model has transformed the price of these calls for our customers and now we are making them even more affordable to you on the SeekingAlpha Marketplace for only $75 per month.

Become the newest subscriber to “Become the Smart Money” here and gain access to all of these : Link

Transcript 1: Understanding the current standard of care in the metastatic castration-resistant prostate cancer (market including Zytiga, Xtandi and Docetaxel

Ticker: OTCPK:ALPMY, JNJ, ECYT, PGNX, PFE

Who's the Expert?

  • Urologic Oncologist with over 21 years of experience, Attending Physician in the Department of Urology at Mount Sinai Beth Israel Medical Center and Professor of Urology at Icahn School of Medicine at Mount Sinai.
  • Currently manages 1000 patients with NMIBC and 100 patients with metastatic castration-resistant prostate cancer.
  • Has authored over 150 papers and participated in many clinical trials for new drugs for urologic disorders.

Interview Goal: This conversation will focus on the current standard of care and how treatments such as Zytiga/Xtandi and Docetaxel are selected for patients.

Link to original project page on Slingshot Insights with questions asked: link

Transcript 2: Exploring the potential of the NOVAVAX Respiratory Syncytial Virus (RSV) vaccine pipeline

Ticker: NVAX

Who's the Expert?

  • Professor and Chairman of our Department of Medicine at MUSC.
  • Clinical research interests revolve around establishing management strategies for patients with common gastrointestinal problems, especially GI bleeding, and the overall direction of these studies has been to help establish national patient management guidelines.
  • Has authored more than 200 scientific papers dealing with GI-related topics and has presented many invited lectures at gastroenterology and hepatology symposia around the United States and throughout the world.

Interview Goal:

To better understand the potential of the current vaccines in development for the Respiratory Syncytial Virus by NOVAVAX (NVAX) including the ResVax vaccine for infants via maternal immunization.

Link to original project page on Slingshot Insights with questions asked: link

Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.